阿纳基纳
医学
巨噬细胞活化综合征
成人斯蒂尔病
不利影响
内科学
疾病
胃肠病学
糖皮质激素
并发症
中止
外科
儿科
疾病严重程度
作者
Jiaxian Guo,Haojie Xu,Weiwei Li,Ying Wang,Yi Zhang,Yuan Jia,Yuan An,Huaqun Zhu
标识
DOI:10.1111/1756-185x.70927
摘要
OBJECTIVE: To investigate the efficacy and safety of add-on anakinra for severe Still's disease complicated by macrophage activation syndrome (MAS) in a real-world setting. METHODS: Consecutive patients aged ≥ 16 years with Still's disease and MAS (HLH-2004 criteria adapted for rheumatic diseases) who received anakinra 100 mg subcutaneously once daily were enrolled. Outcomes were CID, remission, and four EULAR/PReS-aligned targets, assessed at baseline, Day 7, Week 4, Month 3, and Month 6. Glucocorticoid (GC) dose was standardized to prednisone-equivalent mg/kg/day. RESULTS: Eight women (mean age 29.9 ± 12.8 years) were included, and anakinra was initiated at the time of MAS diagnosis in six patients, 2 months after MAS diagnosis in one and 2 months before MAS onset in one. Of the seven patients starting anakinra at or after MAS onset, all achieved Targets 1 and 2 and CID at a median of 1.5 months (range 1-5), and all maintained remission for ≥ 6 months; no severe adverse events were observed. Mean prednisone-equivalent dose fell from 1.63 ± 0.59 to 0.16 ± 0.09 mg/kg/day (p < 0.01). Four patients discontinued anakinra within 6 months for reasons of cost and access rather than disease flare. CONCLUSION: Add-on therapy with anakinra was associated with rapid achievement of EULAR/PReS targets, sustained remission, and substantial GC sparing in severe Still's disease-associated MAS.
科研通智能强力驱动
Strongly Powered by AbleSci AI